EFCCA Clinical Trial News
EFCCA is pleased to bring you some scientific and medical articles related to IBD for your information. EFCCA cannot accept any liability for the accuracy of the information, or for the use of it. Whilst discussion of potential therapies has academic value, EFCCA would like to remind all readers that no claims are made on the effectiveness or safety of any treatment, and that readers should always consult their healthcare professional if they have any concerns or questions, and before taking any action based on the information.
Information about on-going clinical trial
The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective in reducing the severity of the symptoms to the point of remission in individuals with moderate to severe ulcerative colitis or Crohn’s disease when compared to placebo. The secondary objective is to evaluate if the investigational medicine being studied is effective in sustaining disease remission. Remission means absence or sustained reduction of symptoms.
- 18 to 65 years of age
- Diagnosed with: moderate to severe ulcerative colitis for three months or longer or moderate to severe Crohn’s disease for six months or longer
- Experienced an unsatisfactory response to medications to treat your condition i.e., your symptoms continued despite treatment or your symptoms came back while still on treatment or you experienced negative side effects.
There are other eligibility requirements that the study doctor will review with you if you are interested in participating in this study. Only the study doctor can determine whether you are eligible to participate in the study or not.
Patients who qualify and wish to get more information could receive an initial study-related consultation, study-related examinations, and active study medication and /or placebo (an inactive substance).
Find out if you may be eligible to participate in an inflammatory bowel disease clinical research study.
For ulcerative colitis you can also visit:
For Crohn’s disease you can also visit:
Thank you for your interest in clinical research. Participants in clinical research play an integral role in developing potentially better ways to treat various medical conditions.
As many of us unfortunately know, fatigue is said to be one of the ‘big three’ symptoms of IBD (pain, fatigue, and urgently needing the toilet).
As several important articles note that anaemia may be especially significant in people with IBD, EFCCA, supported by Vifor Pharmaceuticals and A+A Research, are currently carrying out a survey to understand:
- The effects of anaemia in IBD from the patient’s perspective
- The effect of fatigue on a variety of activities in daily life
- How healthcare professionals approach and communicate anaemia in IBD
With the knowledge from this focused survey, we hope to be able to gain more detail about the precise impact that this symptom has, which could help us better understand the problem, raise awareness, and capture the attention of those in a position to help us with the aspects of daily life that are affected.
Take part in this exciting survey at: http://www.efcca-solutions.net/anaemia/